A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis
暂无分享,去创建一个
R. Sachidanandam | M. Kracikova | S. Aaronson | G. Akiri | A. George | Ajish George | S A Aaronson | Stuart A. Aaronson | M Kracikova | G Akiri | A George | R Sachidanandam
[1] Lewis A. Chodosh,et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis , 2007, Nature Cell Biology.
[2] B. Kennedy,et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.
[3] Fergus J Couch,et al. p53 Mediates Repression of the BRCA2 Promoter and Down-regulation of BRCA2 mRNA and Protein Levels in Response to DNA Damage* , 2003, The Journal of Biological Chemistry.
[4] Andrew W. Millar,et al. Rethinking clinical trials for cytostatic drugs , 2003, Nature Reviews Cancer.
[5] Judith Roth,et al. A polymorphic microsatellite that mediates induction of PIG3 by p53 , 2002, Nature Genetics.
[6] G. Lozano,et al. Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo , 2011, The Journal of pathology.
[7] M. Stampfer,et al. Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[8] Alan R. Fersht,et al. Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.
[9] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Pietenpol,et al. Kinetics of p53 Binding to Promoter Sites In Vivo , 2001, Molecular and Cellular Biology.
[11] A Sewing,et al. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.
[12] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[13] Eduardo Sontag,et al. Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.
[14] P. Ouillette,et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.
[15] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[16] R. Iggo,et al. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Oren,et al. Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.
[18] R. Eils,et al. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis , 2004, The Journal of cell biology.
[19] T. Lawrence,et al. Global Genechip Profiling to Identify Genes Responsive to p53-Induced Growth Arrest and Apoptosis in Human Lung Carcinoma Cells , 2003, Cancer biology & therapy.
[20] C. Tse,et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.
[21] Gema Moreno-Bueno,et al. Transcriptional profiling of MCF7 breast cancer cells in response to 5‐Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53 , 2006, International journal of cancer.
[22] S. Lowe,et al. The p53–Bcl-2 connection , 2006, Cell Death and Differentiation.
[23] C. Prives,et al. Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.
[24] J. Wiels,et al. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis , 2011, Cell Death and Disease.
[25] H. Abaan,et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.
[26] T. Hunter,et al. Nuclear Translocation of Caspase-3 Is Dependent on Its Proteolytic Activation and Recognition of a Substrate-like Protein(s)* , 2005, Journal of Biological Chemistry.
[27] G. Evan,et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.
[28] Peter K. Sorger,et al. Measuring and Modeling Apoptosis in Single Cells , 2011, Cell.
[29] Luquan Wang,et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression , 2003, Oncogene.
[30] Karen H. Vousden,et al. p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.
[31] David P. Lane,et al. Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.
[32] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[33] Augusto Silva,et al. Double Bolt Regulation of Rad51 by p53: A Role for Transcriptional Repression , 2006, Cell cycle.
[34] L. Vassilev,et al. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation , 2011, Oncogene.
[35] Yves Pommier,et al. γH2AX and cancer , 2008, Nature Reviews Cancer.
[36] D. Notterman,et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.
[37] E. Appella,et al. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[38] Qiang Yu,et al. p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[39] D. Ginsberg,et al. p53 and E2f: partners in life and death , 2009, Nature Reviews Cancer.
[40] Sam W. Lee,et al. Influence of Induced Reactive Oxygen Species in p53-Mediated Cell Fate Decisions , 2003, Molecular and Cellular Biology.
[41] K. Vousden,et al. Coping with stress: multiple ways to activate p53 , 2007, Oncogene.
[42] O. Pereira-smith,et al. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. , 2006, Cancer research.
[43] S. Aaronson,et al. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma , 2009, Oncogene.
[44] X. Chen,et al. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.
[45] G. Evan,et al. Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.
[46] F. Murray-Zmijewski,et al. A complex barcode underlies the heterogeneous response of p53 to stress , 2008, Nature Reviews Molecular Cell Biology.
[47] T. Sasagawa,et al. Characterization of adriamycin-induced G2 arrest and its abrogation by caffeine in FL-amnion cells with or without p53. , 2001, Experimental cell research.
[48] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.